Heterologous DNA-prime/protein-boost immunization with a monomeric SARS-CoV-2 spike antigen redundantizes the trimeric receptor-binding domain structure to induce neutralizing antibodies in old mice

A multitude of alterations in the old immune system impair its functional integrity. Closely related, older individuals show, for example, a reduced responsiveness to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines. However, systematic strategies to specifically improve the efficacy of vaccines in the old are missing or limited to simple approaches like increasing the antigen concentration or injection frequencies. We here asked whether the intrinsic, trimeric structure of the SARS-CoV-2 spike (S) antigen and/or a DNA- or protein-based antigen delivery platform affects priming of functional antibody responses particularly in old mice. The used S-antigens were primarily defined by the presence/absence of the membrane-anchoring TM domain and the closely interlinked formation/non-formation of a trimeric structure of the receptor binding domain (S-RBD). Among others, we generated vectors expressing prefusion-stabilized, cell-associated (TM+) trimeric “S2-P” or secreted (TM−) monomeric “S6-PΔTM” antigens. These proteins were produced from vector-transfected HEK-293T cells under mild conditions by Strep-tag purification, revealing that cell-associated but not secreted S proteins tightly bound Hsp73 and Grp78 chaperones. We showed that both, TM-deficient S6-PΔTM and full-length S2-P antigens elicited very similar S-RBD-specific antibody titers and pseudovirus neutralization activities in young (2–3 months) mice through homologous DNA-prime/DNA-boost or protein-prime/protein-boost vaccination. The trimeric S2-P antigen induced high S-RBD-specific antibody responses in old (23-24 months) mice through DNA-prime/DNA-boost vaccination. Unexpectedly, the monomeric S6-PΔTM antigen induced very low S-RBD-specific antibody titers in old mice through homologous DNA-prime/DNA-boost or protein-prime/protein-boost vaccination. However, old mice efficiently elicited an S-RBD-specific antibody response after heterologous DNA-prime/protein-boost immunization with the S6-PΔTM antigen, and antibody titers even reached similar levels and neutralizing activities as in young mice and also cross-reacted with different S-variants of concern. The old immune system thus distinguished between trimeric and monomeric S protein conformations: it remained antigen responsive to the trimeric S2-P antigen, and a simple change in the vaccine delivery regimen was sufficient to unleash its reactivity to the monomeric S6-PΔTM antigen. This clearly shows that both the antigen structure and the delivery platform are crucial to efficiently prime humoral immune responses in old mice and might be relevant for designing “age-adapted” vaccine strategies.

[1]  Dae-Sun Kim,et al.  Analyzing immune responses to varied mRNA and protein vaccine sequences , 2023, NPJ vaccines.

[2]  J. Nguyen-Van-Tam,et al.  Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A Randomised Controlled Trial , 2023, Journal of Infection.

[3]  Hangwen Li,et al.  Long-Term Cross Immune Response in Mice following Heterologous Prime-Boost COVID-19 Vaccination with Full-Length Spike mRNA and Recombinant S1 Protein , 2023, Vaccines.

[4]  S. Fukushi,et al.  Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain , 2023, Nature Communications.

[5]  Li Yang,et al.  Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5‐included SARS‐CoV‐2 variants than homologous vaccination of mRNA vaccine , 2023, MedComm.

[6]  Kun Xu,et al.  A systematic review and meta-analysis of the effectiveness and safety of COVID-19 vaccination in older adults , 2023, Frontiers in Immunology.

[7]  S. Chatterjee,et al.  Association of COVID-19 with Comorbidities: An Update , 2023, ACS pharmacology & translational science.

[8]  M. Colombo,et al.  Receptor‐binding domain‐based SARS‐CoV‐2 vaccine adjuvanted with cyclic di‐adenosine monophosphate enhances humoral and cellular immunity in mice , 2023, Journal of medical virology.

[9]  William T. Harvey,et al.  SARS-CoV-2 variant biology: immune escape, transmission and fitness , 2023, Nature Reviews Microbiology.

[10]  Michael E. DeWitt,et al.  Frailty impacts immune responses to Moderna COVID-19 mRNA vaccine in older adults , 2023, Immunity & Ageing.

[11]  A. Jin,et al.  Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice , 2022, iScience.

[12]  Yuhang Jiang,et al.  A Vaccine of SARS-CoV-2 S Protein RBD Induces Protective Immunity , 2022, International journal of molecular sciences.

[13]  G. Rimmelzwaan,et al.  Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults , 2022, Nature Aging.

[14]  Siti Norussaadah Mohd Salleh,et al.  Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose , 2022, Nature Communications.

[15]  Bin Zhou,et al.  Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial , 2022, The Lancet Infectious Diseases.

[16]  I. Shimomura,et al.  GRP78, a Novel Host Factor for SARS-CoV-2: The Emerging Roles in COVID-19 Related to Metabolic Risk Factors , 2022, Biomedicines.

[17]  F. Kirchhoff,et al.  BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults , 2022, Frontiers in Immunology.

[18]  S. Hägg,et al.  COVID vaccination in older adults , 2022, Nature Microbiology.

[19]  Wenjun Liu,et al.  The Cross-Protective Immunity Landscape Among Different SARS-CoV-2 Variant RBDs , 2022, Frontiers in Immunology.

[20]  Chia-Yeh Liu,et al.  Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy , 2022, Journal of biomedical science.

[21]  Jim Q. Ho,et al.  COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes , 2022, Frontiers in Immunology.

[22]  M. Worobey,et al.  Competent immune responses to SARS-CoV-2 variants in older adults following two doses of mRNA vaccination , 2022, Nature Communications.

[23]  Li-Li Liu,et al.  A Third Dose of an Inactivated Vaccine Dramatically Increased the Levels and Decay Times of Anti-SARS-CoV-2 Antibodies, but Disappointingly Declined Again: A Prospective, Longitudinal, Cohort Study at 18 Serial Time Points Over 368 Days , 2022, Frontiers in Immunology.

[24]  M. Llorian,et al.  Impaired immune response drives age-dependent severity of COVID-19 , 2022, bioRxiv.

[25]  K. Giri,et al.  Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India , 2022, The Lancet.

[26]  B. B. Stocks,et al.  Characterization of a SARS-CoV-2 spike protein reference material , 2022, Analytical and Bioanalytical Chemistry.

[27]  F. Kashanchi,et al.  Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy , 2022, Medical Microbiology and Immunology.

[28]  D. Montefiori,et al.  Homologous and Heterologous Covid-19 Booster Vaccinations , 2022, The New England journal of medicine.

[29]  F. Kirchhoff,et al.  Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants , 2021, EBioMedicine.

[30]  H. Jäck,et al.  The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic , 2021, Cell.

[31]  D. C. Swarts,et al.  Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants , 2021, mBio.

[32]  D. Tsiantoulas,et al.  The Dynamics of B Cell Aging in Health and Disease , 2021, Frontiers in Immunology.

[33]  Bärbel Camara,et al.  Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults , 2021, Nature Microbiology.

[34]  E. Verdin,et al.  SARS-CoV-2, COVID-19 and the aging immune system , 2021, Nature Aging.

[35]  F. Cosset,et al.  Immunogenicity and efficacy of          heterologous ChAdOx1–BNT162b2 vaccination , 2021, Nature.

[36]  V. Libri,et al.  Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial , 2021, The Lancet.

[37]  J. Klingström,et al.  Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination , 2021, The New England journal of medicine.

[38]  J. Münch,et al.  Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination , 2021, Nature Medicine.

[39]  L. Vaca,et al.  SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants , 2021, Frontiers in Immunology.

[40]  X. Xia Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines , 2021, Vaccines.

[41]  Chaim A. Schramm,et al.  Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants , 2021, Science.

[42]  Frances E. Muldoon,et al.  Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 , 2021, Nature.

[43]  J. Chou,et al.  A Trimeric Hydrophobic Zipper Mediates the Intramembrane Assembly of SARS-CoV-2 Spike , 2021, Journal of the American Chemical Society.

[44]  M. Cho,et al.  A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain , 2021, Frontiers in Immunology.

[45]  D. Gong,et al.  Enhancing the Prefusion Conformational Stability of SARS-CoV-2 Spike Protein Through Structure-Guided Design , 2021, Frontiers in Immunology.

[46]  C. Shin,et al.  Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice , 2021, Vaccines.

[47]  K. Subbarao,et al.  Vaccines for older adults , 2021, BMJ.

[48]  Charles Y. Tan,et al.  BNT162b vaccines protect rhesus macaques from SARS-CoV-2 , 2021, Nature.

[49]  N. Patel,et al.  SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice , 2021, Nature Communications.

[50]  R. Varadarajan,et al.  Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative , 2021, bioRxiv.

[51]  Arlo Z. Randall,et al.  Diverse Humoral Immune Responses in Younger and Older Adult COVID-19 Patients , 2021, medRxiv.

[52]  K. Machida,et al.  The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection , 2021, Journal of Biological Chemistry.

[53]  Shixia Wang,et al.  DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses , 2021, Emerging microbes & infections.

[54]  Xiaojie Shi,et al.  Neutralizing antibodies targeting SARS-CoV-2 spike protein , 2020, Stem Cell Research.

[55]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[56]  B. Blomberg,et al.  Aging induces B cell defects and decreased antibody responses to influenza infection and vaccination , 2020, Immunity & ageing : I & A.

[57]  Yunwei Lou,et al.  The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens , 2020, Frontiers in Immunology.

[58]  R. Baric,et al.  Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults , 2020, The New England journal of medicine.

[59]  M. Beltramello,et al.  Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.

[60]  J. Schrag,et al.  Rapid, high-yield production of full-length SARS-CoV-2 spike ectodomain by transient gene expression in CHO cells , 2020, bioRxiv.

[61]  J. Diallo,et al.  Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization , 2020, Membranes.

[62]  Yuquan Wei,et al.  A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity , 2020, Nature.

[63]  Ilya J. Finkelstein,et al.  Structure-based design of prefusion-stabilized SARS-CoV-2 spikes , 2020, Science.

[64]  L. Renault,et al.  Stabilizing the closed SARS-CoV-2 spike trimer , 2020, Nature Communications.

[65]  A. Sette,et al.  The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients , 2020, Science Immunology.

[66]  M. Fain,et al.  SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes , 2020, GeroScience.

[67]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[68]  Shiliang Ma,et al.  B Cell Dysfunction Associated With Aging and Autoimmune Diseases , 2019, Front. Immunol..

[69]  R. Schirmbeck,et al.  Cationic domains in particle-forming and assembly-deficient HBV core antigens capture mammalian RNA that stimulates Th1-biased antibody responses by DNA vaccination , 2018, Scientific Reports.

[70]  N. Petrovsky,et al.  DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant. , 2017, The Journal of general virology.

[71]  Fang Li,et al.  Structure, Function, and Evolution of Coronavirus Spike Proteins. , 2016, Annual review of virology.

[72]  A. Mondal,et al.  The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination , 2014, Human vaccines & immunotherapeutics.

[73]  R. Viscidi,et al.  Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates. , 2013, Viral immunology.

[74]  B. Blomberg,et al.  In senescence, age‐associated B cells secrete TNFα and inhibit survival of B‐cell precursors * , 2013, Aging cell.

[75]  M. Cancro,et al.  A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. , 2011, Blood.

[76]  J. Arthos,et al.  Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. , 2010, Vaccine.

[77]  Hongxiang Sun,et al.  ISCOMs and ISCOMATRIX. , 2009, Vaccine.

[78]  Shan Lu Heterologous prime-boost vaccination. , 2009, Current opinion in immunology.

[79]  C. Siegrist,et al.  B-cell responses to vaccination at the extremes of age , 2009, Nature Reviews Immunology.

[80]  R. Vaughan,et al.  B-cell diversity decreases in old age and is correlated with poor health status , 2009, Aging cell.

[81]  S. Kochanek,et al.  Recombinant complexes of antigen with stress proteins are potent CD8 T-cell-stimulating immunogens , 2008, Journal of Molecular Medicine.

[82]  D. Weiskopf,et al.  Biology of immune responses to vaccines in elderly persons. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[83]  Giuseppe Altavilla,et al.  DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. , 2006, Vaccine.

[84]  Kim L Kusser,et al.  Age-related Defects in CD4 T Cell Cognate Helper Function Lead to Reductions in Humoral Responses , 2004, The Journal of experimental medicine.

[85]  R. Rappuoli,et al.  Synthesis and Characterization of a Native, Oligomeric Form of Recombinant Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein , 2004, Journal of Virology.

[86]  T. Randall,et al.  CD4 T cell memory derived from young naive cells functions well into old age, but memory generated from aged naive cells functions poorly , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[87]  J. Reimann,et al.  Priming polyvalent immunity by DNA vaccines expressing chimeric antigens with a stress protein‐capturing, viral J‐domain , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[88]  J. Reimann,et al.  Truncated or chimeric endogenous protein antigens gain immunogenicity for B cells by stress protein‐facilitated expression , 1999, European journal of immunology.

[89]  S. Green,et al.  Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. , 2008, Vaccine.